These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 23070117)

  • 21. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
    Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
    Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
    Zhu H; You Y; Shen Z; Shi L
    Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen.
    Ohno M; Natsume A; Ichiro Iwami K; Iwamizu H; Noritake K; Ito D; Toi Y; Ito M; Motomura K; Yoshida J; Yoshikawa K; Wakabayashi T
    Cancer Sci; 2010 Dec; 101(12):2518-24. PubMed ID: 20880333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
    Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric Antigen Receptor T Cells for Glioblastoma: Current Concepts, Challenges, and Future Perspectives.
    Karschnia P; Teske N; Thon N; Subklewe M; Tonn JC; Dietrich J; von Baumgarten L
    Neurology; 2021 Aug; 97(5):218-230. PubMed ID: 33986138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer.
    Li N; Liu S; Sun M; Chen W; Xu X; Zeng Z; Tang Y; Dong Y; Chang AH; Zhao Q
    Transl Oncol; 2018 Feb; 11(1):11-17. PubMed ID: 29132013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
    Hegde M; Mukherjee M; Grada Z; Pignata A; Landi D; Navai SA; Wakefield A; Fousek K; Bielamowicz K; Chow KK; Brawley VS; Byrd TT; Krebs S; Gottschalk S; Wels WS; Baker ML; Dotti G; Mamonkin M; Brenner MK; Orange JS; Ahmed N
    J Clin Invest; 2016 Aug; 126(8):3036-52. PubMed ID: 27427982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours.
    Hsu K; Middlemiss S; Saletta F; Gottschalk S; McCowage GB; Kramer B
    Cancer Gene Ther; 2021 Apr; 28(3-4):321-334. PubMed ID: 32873870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
    Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
    Front Immunol; 2022; 13():867154. PubMed ID: 35603195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.
    Choi BD; Suryadevara CM; Gedeon PC; Herndon JE; Sanchez-Perez L; Bigner DD; Sampson JH
    J Clin Neurosci; 2014 Jan; 21(1):189-90. PubMed ID: 24054399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts.
    Tóth G; Szöllősi J; Abken H; Vereb G; Szöőr Á
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
    Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.
    Lazovic J; Jensen MC; Ferkassian E; Aguilar B; Raubitschek A; Jacobs RE
    Clin Cancer Res; 2008 Jun; 14(12):3832-9. PubMed ID: 18559603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.
    Shiina S; Ohno M; Ohka F; Kuramitsu S; Yamamichi A; Kato A; Motomura K; Tanahashi K; Yamamoto T; Watanabe R; Ito I; Senga T; Hamaguchi M; Wakabayashi T; Kaneko MK; Kato Y; Chandramohan V; Bigner DD; Natsume A
    Cancer Immunol Res; 2016 Mar; 4(3):259-68. PubMed ID: 26822025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
    Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
    J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
    Ren PP; Li M; Li TF; Han SY
    Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.